Study S000570

The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents

ClinicalTrials.gov record

Registration

Registration: NCT01076842
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 75
Start: 2008-04
Primary completion: 2011-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Type 2
Interventions: DRUG:Insulin-Levemir; DRUG:Exenatide-Bayetta; DRUG:Insulin-Levemir and Exenatide-Bayetta; DEVICE:SenseWear Pro3® armband; DEVICE:DexCom CGM
Results posted: FALSE

Registered primary outcomes

The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks. [1 month]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.